Product analysis
SAMe 400 may support joint comfort, although the benefit findings are limited and come from specific clinical settings. Its unstated preparation makes stability and absorption harder to judge.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality20
The specific SAMe form is not stated, leaving its quality uncertain. The ingredient name alone does not establish stability or absorption comparable to the preparations behind the benefit findings.
Ingredient Transparency63
The SAMe amount is disclosed, allowing a serving-amount comparison. Its form is unstated, which leaves the preparation less clear.
Value For Money80
SAMe offers favorable value for the amount supplied. That price comparison does not resolve uncertainty about the preparation.
Customer Satisfaction81
Customer feedback is positive across a large review pool. The volume provides a broad picture of satisfaction, without proving health benefits.
Product Focus71
The formula stays focused on SAMe, with limited support for joint comfort in specific settings. Everyday mood and stress benefits remain uncertain, and liver-related findings do not establish routine detoxification.
- Format
Tablet - Container
- 30 Tablet(s)
- Per serving
- $0.80
- Also available
SAMe 200$15.00- Customer rating
- 4.5 · 3,104 ratings
Goals
Impact
High effect
SAMe · 400 mg
Impact
Highest effect
SAMe · 400 mg
Impact
Moderate effect
SAMe · 400 mg
Impact
High effect
SAMe · 400 mg
SAMe Not classified
No linked studies yet.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
S-Adenosyl Methionine | 400 mg |
SAMe · 400 mg OverallScore96
400 mg of SAMe per serving comes at a moderate cost for the amount. The source includes SAMe Tosylate Disulfate, but its proportion is unclear. Blister packaging helps protect it from moisture. The active amount is disclosed.
How this ingredient is rated
Active Ingredient Quality & Bioavailability100
The SAMe source includes SAMe Tosylate Disulfate; its share is not stated. Blister packaging helps protect SAMe from moisture.
Stabilized Salt Form
The SAMe source includes SAMe Tosylate Disulfate; its share is not stated.
Packaging Integrity
Blister packaging helps protect SAMe from moisture.
Dose, Safety & Label Transparency100
The serving lists 400 mg of SAMe. The active SAMe amount is stated separately from its salt.
Active Dosage Strength
The serving lists 400 mg of SAMe.
Net SAMe Yield Transparency
The active SAMe amount is stated separately from its salt.
Value80
The cost for the listed SAMe amount is moderate.
Price Per 400mg Active Dose
The cost for the listed SAMe amount is moderate.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].
- Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease.
- Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.
- A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis.
- Exploring the mechanisms behind S-adenosylmethionine (SAMe) in the treatment of osteoarthritis.
- Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
- Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
- S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
- Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
- S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
- Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
- A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
- Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression.
- S-adenosylmethionine blood levels in major depression: changes with drug treatment.
- Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.